Concepedia

Author

Sundar Neelakantan

University of Kentucky

Also Known As

Neelakantan, S., S. Neelakantan, Sundar Neelakantan

18

Publications

1K

Citations

9

H-Index

15

Concepts

All Affiliations

University of KentuckyIndiana University – Purdue University IndianapolisIndiana University School of MedicineUniversity of RochesterDana-Farber Cancer Institute
SN

About

Sundar Neelakantan is an author at University of Kentucky specializing in drug discovery, pharmacology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

199

2

Natural Sciences

1

1

11

3

Biochemistry

1

1

11

4

Immunology

1

1

188

5

Molecular Biology

1

1

11

Sundar Neelakantan

×

9

Publications

988

Citations

9

H-Index

YearCitations

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells

Mónica L. Guzmán, Randall M. Rossi, Sundar Neelakantan,

Blood

2007

407

Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1)

Sundar Neelakantan, Shama Nasim, Mónica L. Guzmán,

Bioorganic & Medicinal Chemistry Letters

2009

188

The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target

Saman Hewamana, Suhair Alghazal, Thet Thet Lin,

Blood

2008

154

A water soluble parthenolide analog suppresses <i>in vivo</i> tumor growth of two tobacco‐associated cancers, lung and bladder cancer, by targeting NF‐κB and generating reactive oxygen species

Rajasubramaniam Shanmugam, Praveen Kusumanchi, Hitesh Appaiah,

International Journal of Cancer

2010

74

A water‐soluble parthenolide analogue suppresses in vivo <i>prostate cancer</i> growth by targeting NFκB and generating reactive oxygen species

Rajasubramaniam Shanmugam, Praveen Kusumanchi, Liang Cheng,

The Prostate

2010

66

Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition<i>in vivo</i>

Michele Yip-Schneider, Huangbing Wu, Matthew Ralstin,

Molecular Cancer Therapeutics

2007

38

Effect of Celecoxib and the Novel Anti-Cancer Agent, Dimethylamino-Parthenolide, in a Developmental Model of Pancreatic Cancer

Michele Yip-Schneider, Huangbing Wu, Victor Njoku,

Pancreas

2008

29

Nuclear factor‐κB as a potential therapeutic target for the novel cytotoxic agent LC‐1 in acute myeloid leukaemia

Christopher Jenkins, Saman Hewamana, Amanda Gilkes,

British Journal of Haematology

2008

21

Spectrophotometric and Steady-State Kinetic Analysis of the Biosynthetic Arginine Decarboxylase of <i>Yersinia pestis</i> Utilizing Arginine Analogues as Inhibitors and Alternative Substrates

Paul Balbo, Chandra N. Patel, Korie G. Sell,

Biochemistry

2003

11

Page 1